Psychedellic Assisted Psychotherapy - an Interview with Alexa Altman, Ph.D. - Ep 677
Dr. Reedy welcomes Dr. Alexa Altman where she discusses how psychedelics bring the unconscious material into consciousness. She talks about the importance of integration.
Dr. Altman’s Website: https://www.i-psychedelic.com
1. Single-dose psilocybin (25 mg) with psychological support for MDDJAMA – “Single-Dose Psilocybin Treatment for Major Depressive Disorder” psychiatryonline.org+15sunstonetherapies.com+15pmc.ncbi.nlm.nih.gov+15 Summary: Demonstrated strong antidepressant effects and good tolerability over follow-up. Email:
[email protected]
2. One-Year Follow-Up of Psilocybin for Depression
Study: Long-term effects of psilocybin therapy for depression
Johns Hopkins – “Psilocybin treatment for major depression effective for up to a year” Summary: 67% of participants remained in remission one year post-treatment.
3. MDMA-Assisted Therapy for Severe PTSD
Randomized, placebo-controlled MDMA-assisted therapy
Nature Medicine – “MDMA-assisted therapy for severe PTSD” Summary: Significant reduction in PTSD symptoms, well‑tolerated in a diverse cohort.
Contact (MAPS / Lykos Therapeutics): Email:
[email protected]
4. Psilocybin for Cancer-Related Anxiety & Depression
Psilocybin in patients with life-threatening cancer
PMC – “High-dose psilocybin produced large decreases in depressed mood and anxiety…” Summary: 80% of participants maintained significant symptom relief at 6 months. Website: heffter.org (contact via site) en.wikipedia.org
1. Johns Hopkins University
Center for Psychedelic and Consciousness Research
Psilocybin for depression, anxiety, addiction, and end-of-life distress
Why it’s top-tier: The first major U.S. institution to receive regulatory approval for psychedelic research in modern times. 🔗 hopkinspsychedelic.org
2. Imperial College London
Centre for Psychedelic Research
Psilocybin for treatment-resistant depression, brain imaging, DMT studies
Why it’s top-tier: Home of pioneering neuroimaging studies on psychedelics; led by Robin Carhart-Harris (now at UCSF). 🔗 imperial.ac.uk
3. Multidisciplinary Association for Psychedelic Studies (MAPS)
MDMA for PTSD (now in Phase 3 trials), harm reduction, global education
Why it’s top-tier: MAPS initiated the first FDA-approved Phase 3 trials for MDMA-assisted therapy. 🔗 maps.org
4. University of California, San Francisco
Psychedelic Research Program
Psilocybin, DMT, ibogaine; Robin Carhart-Harris now leads U.S. arm
Why it’s top-tier: Integrates neuroscience, clinical psychology, and pharmacology. 🔗 psychedelics.ucsf.edu
5. NYU Langone Health
Center for Psychedelic Medicine
End-of-life anxiety, alcoholism, PTSD, and psilocybin studies
Why it’s top-tier: Known for rigorous clinical trials and major collaborations. 🔗 med.nyu.edu
6. University of California, Los Angeles
UCLA Psychedelic Studies Initiative
Psilocybin + CBT, anxiety, clinical protocols
Why it’s top-tier: Conducting one of the few FDA-regulated psilocybin trials with integrated therapy. 🔗 uclapsi.org
7. University of Wisconsin–Madison / Usona Institute
Psilocybin for major depression (FDA Phase 3 trials)
Why it’s top-tier: Leading U.S.-based nonprofit with regulatory traction and major academic partnerships. 🔗 usonainstitute.org
8. Massachusetts General Hospital / Harvard Medical School
Center for the Neuroscience of Psychedelics
Neurobiological mechanisms of psychedelics
Why it’s top-tier: Combines Harvard academic leadership with Mass General clinical infrastructure. 🔗 massgeneral.org
9. University of New Mexico
Psychedelic-Assisted Therapies & Research Group
Ketamine, DMT, and MDMA research; Indigenous-informed approaches
Why it’s top-tier: Interdisciplinary and trauma-informed program with cultural awareness. 🔗 hsc.unm.edu
10. Oregon Health & Science University
State-licensed psilocybin therapy programs, public health, training
Why it’s top-tier: One of the first institutions engaging with psilocybin therapy post-legalization under Measure 109. 🔗 ohsu.edu
Canada - english